Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study

Gramatzki, Dorothee; Roth, Patrick; Rushing, Elisabeth J.; Weller, Jonathan; Andratschke, Nicolaus; Höfer, Silvia; Korol, Dimitri; Regli, Luca; Pangalu, Athina; Pless, Miklos; Oberle, Joachim; Bernays, René L.; Moch, Holger; Rohrmann, Sabine; Weller, Michael

doi:10.1093/annonc/mdy106

Cited by 86 publications

(70 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A combination of bevacizumab and lomustine is considered for treatment of recurrent GBM patients with rapidly progressing disease [ 55 ]. However, in most cases, these chemotherapies either in combination or alone have failed to show prolongation of overall survival in recurrent GBM patients [ 56 , 57 ]. Therefore, irrespective of the treatment method, most patients diagnosed with primary GBM die within two years.…”

Section: Treatment Options For Gbm/history Of Gbm Treatmentmentioning

confidence: 99%

Radioresistance in Glioblastoma and the Development of Radiosensitizers

Ali

Oliva

Noman

et al. 2020

Cancers

107

View full text Add to dashboard Cite

Ionizing radiation is a common and effective therapeutic option for the treatment of glioblastoma (GBM). Unfortunately, some GBMs are relatively radioresistant and patients have worse outcomes after radiation treatment. The mechanisms underlying intrinsic radioresistance in GBM has been rigorously investigated over the past several years, but the complex interaction of the cellular molecules and signaling pathways involved in radioresistance remains incompletely defined. A clinically effective radiosensitizer that overcomes radioresistance has yet to be identified. In this review, we discuss the current status of radiation treatment in GBM, including advances in imaging techniques that have facilitated more accurate diagnosis, and the identified mechanisms of GBM radioresistance. In addition, we provide a summary of the candidate GBM radiosensitizers being investigated, including an update of subjects enrolled in clinical trials. Overall, this review highlights the importance of understanding the mechanisms of GBM radioresistance to facilitate the development of effective radiosensitizers.

show abstract

Section: Treatment Options For Gbm/history Of Gbm Treatmentmentioning

confidence: 99%

Radioresistance in Glioblastoma and the Development of Radiosensitizers

Ali

Oliva

Noman

et al. 2020

Cancers

107

View full text Add to dashboard Cite

show abstract

“…Bevacizumab (Avastin), an anti-VEGF antibody, has been shown to be effective in the treatment of a number of solid cancers, including metastatic colorectal cancer, renal cell cancer and non-small cell lung cancer [37][38][39][40]. Bevacizumab has been approved for use in the treatment of GBM, despite reports of limited improvement in overall survival [41][42][43]. A Phase III study has reported an increase in progression-free survival and improved quality of life, however, an increase in adverse events in patients receiving bevacizumab compared to a placebo was also observed [41,42].…”

Section: Advances In Treatments For Gbmmentioning

confidence: 99%

“…Bevacizumab has been approved for use in the treatment of GBM, despite reports of limited improvement in overall survival [41][42][43]. A Phase III study has reported an increase in progression-free survival and improved quality of life, however, an increase in adverse events in patients receiving bevacizumab compared to a placebo was also observed [41,42].…”

Section: Advances In Treatments For Gbmmentioning

confidence: 99%

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma

Tea

Poonnoose

Pitson

2020

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most commonly diagnosed malignant brain tumor in adults. The prognosis for patients with GBM remains poor and largely unchanged over the last 30 years, due to the limitations of existing therapies. Thus, new therapeutic approaches are desperately required. Sphingolipids are highly enriched in the brain, forming the structural components of cell membranes, and are major lipid constituents of the myelin sheaths of nerve axons, as well as playing critical roles in cell signaling. Indeed, a number of sphingolipids elicit a variety of cellular responses involved in the development and progression of GBM. Here, we discuss the role of sphingolipids in the pathobiology of GBM, and how targeting sphingolipid metabolism has emerged as a promising approach for the treatment of GBM.

show abstract

“…Initial clinical studies of glioblastoma showed that bevacizumab delayed progression from ~7 to ~10 months, but did not impact overall survival (~16 months) [1]. Others found similar results [2]. Newer bevacizumab regimens with 100 mg/m 2 /day cycles of temozolomide and newer studies of lower bevacizumab doses have indicated some survival benefits [3].…”

Section: Introductionmentioning

confidence: 99%

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

Kast¹

2018

Medical Sciences

View full text Add to dashboard Cite

During glioblastoma treatment, the pharmaceutical monoclonal antibody to vascular endothelial growth factor A, bevacizumab, has improved the quality of life and delayed progression for several months, but has not (or only marginally) prolonged overall survival. In 2017, several dramatic research papers appeared that are crucial to our understanding of glioblastoma vis-a-vis the mode of action of bevacizumab. As a consequence of these papers, a new, potentially more effective treatment protocol can be built around bevacizumab. This is the ADZT regimen, where four old drugs are added to bevacizumab. These four drugs are apremilast, marketed to treat psoriasis, dapsone, marketed to treat Hansen’s disease, zonisamide, marketed to treat seizures, and telmisartan, marketed to treat hypertension. The ancillary attributes of each of these drugs have been shown to augment bevacizumab. This paper details the research data supporting this contention. Phase three testing of AZDT addition to bevacizumab is required to establish safety and effectiveness before general use.

show abstract

Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study

Cited by 86 publications

References 13 publications

Radioresistance in Glioblastoma and the Development of Radiosensitizers

Radioresistance in Glioblastoma and the Development of Radiosensitizers

Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment

Contact Info

Product

Resources

About